BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34600747)

  • 1. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
    Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
    Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
    Asokan MS; Joan RF; Babji S; Dayma G; Nadukkandy P; Subrahmanyam V; Pandey A; Malagi G; Arya P; Mahajan V; Bhavikatti J; Pawar K; Thorat A; Shah P; Goud RB; Roy B; Rajukutty S; Immanuel S; Agarwal D; Saha S; Shivaraj A; Panikulam P; Shome R; Gulzar SE; Sharma AU; Naik A; Talashi S; Belekar M; Yadav R; Khude P; V M; Shivalingaiah S; Deshmukh U; Bhise C; Joshi M; Inbaraj LR; Chandrasingh S; Ghose A; Jamora C; Karumbati AS; Sundaramurthy V; Johnson A; Ramesh N; Chetan N; Parthiban C; Ahmed A; Rakshit S; Adiga V; D'souza G; Rale V; George CE; John J; Kawade A; Chaturvedi A; Raghunathan A; Dias M; Bhosale A; Raghu P; Shashidhara LS; Vyakarnam A; Bal V; Kang G; Mayor S
    Lancet Reg Health Southeast Asia; 2024 Mar; 22():100361. PubMed ID: 38482152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
    Iwata S; Pollard AJ; Tada Y; Omoto S; Shibata RY; Igarashi K; Hasegawa T; Ariyasu M; Sonoyama T
    Sci Rep; 2024 Apr; 14(1):9830. PubMed ID: 38684712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Responses of SARS-CoV-2 Vaccines amongst Health Care Workers in a Tertiary Care Hospital in Tripura, India: A Cross-Sectional Study.
    Mog C; Bhattacharya S; Baidya S; Das S
    Indian J Community Med; 2022; 47(4):583-586. PubMed ID: 36742975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
    Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
    Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-vaccination analysis of anti-spike antibody responses in kidney transplant recipients with and without COVID-19 infection in a tertiary care centre, India.
    Jasuja S; Jha V; Sagar G; Bahl A; Verma S; Jasuja N; Kaur J
    Clin Kidney J; 2022 Jul; 15(7):1312-1321. PubMed ID: 35747093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines.
    Choudhary HR; Parai D; Chandra Dash G; Kshatri JS; Mishra N; Choudhary PK; Pattnaik D; Panigrahi K; Behera S; Ranjan Sahoo N; Podder S; Mishra A; Raghav SK; Mishra SK; Pradhan SK; Sahoo SK; Pattnaik M; Rout UK; Nanda RR; Mondal N; Kanungo S; Palo SK; Bhattacharya D; Pati S
    Front Med (Lausanne); 2021; 8():778129. PubMed ID: 35004746
    [No Abstract]   [Full Text] [Related]  

  • 12. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study.
    Parai D; Choudhary HR; Dash GC; Behera S; Mishra N; Pattnaik D; Raghav SK; Mishra SK; Sahoo SK; Swain A; Mohapatra I; Pattnaik M; Moharana A; Jena SR; Praharaj I; Subhadra S; Kanungo S; Bhattacharya D; Pati S
    Front Microbiol; 2022; 13():942659. PubMed ID: 36016787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
    Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
    Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Response After Two Doses of COVISHIELD
    Balwani MR; Pasari AS; Bawankule C; Bhawane A; Tolani P; Katekhaye VM
    J Assoc Physicians India; 2023 Sep; 71(9):56-60. PubMed ID: 38700302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.